Lilly makes another move for Verve's genetic medicines, this time buying Beam's opt-in rights
Eli Lilly is once again tapping into Verve Therapeutics, which is developing one-time treatments in the cardiovascular disease space, as the pharma giant continues to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
